Description
1. STRUCTURE-ACTIVITY RELATIONSHIPS (SAR). 2. BRAIN ANTITUMOR AGENTS: THE STORY OF SPIROMUSTIN. 3. PRIVILEGED DRUG SCAFFOLDS: THE STORY OF LC-6 AND PYRIDINOLCARBAMATE. 4. CYTIDINE DEAMINASE: PART 1THE CONCEPT OF TRANSITION-STATE INHIBITORS AND THE DISCOVERY OF ZEBULARINE. 5. CYTIDINE DEAMINASE: PART 2LESSONS FROM NATURES TRANSITION STATE INHIBITORS. 6. TIAZOFURIN AND THE HISTORY OF THIAZOLE-4-CARBOXAMIDE ADENIDE DINUCLEOTIDE (TAD). 7. THE AIDS ERA: NUCLEOSIDE ANTIRETROVIRAL AGENTS. 8. THE AIDS ERA: SYNTHESES OF FLUORONUCLEOSIDES AND THE CLINICAL DEVELOPMENT OF LODENOSINE. 9. EXPLORATION OF NOVEL NUCLEOSIDE TEMPLATES IN SEARCH OF ACTIVE ANTI-HIV AND ANTIVIRAL DRUGS. 10. 3-DEAZANEPLANOCIN A AND CYCLOPENTENYLCYTOSINE. 11. EPIGENETICS AND CANCER: 5-AZA-CYTIDINE AND ZEBULARINE. 12. ZEBULARINE AS AN EPIGENETIC ANTICANCER AGENT. 13. 3-DEAZANEPLANOCIN A (DZNep) AS AN EPIGENETIC ANTICANCER AGENT. 14. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMISTRY. 15. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 1). 16. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART 2)MORE ON KINASES/POLYMERASES AND DRUG DEVELOPMENT OF N-MCT. 17. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: BIOLOGY (PART THREE)INVESTIGATION OF MORE EXOTIC TARGETS. 18. BICYCLO[3.1.0]HEXANE NUCLEOSIDES: CHEMICAL VARIATIONS ON A COMMON THEME. 19. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): A PHARMACOPHORE-GUIDED APPROACH. 20. DIACYLGLYCEROL LACTONES AND PROTEIN KINASE C (PKC): TRANSITION FROM A PHARMACOPHORE-GUIDED APPROACH TO A RECEPTOR-GUIDED APPROACH.
